Methods and compositions for modulating tumor cell activity
AssigneeNational Research Council of Canada
InventorsMaureen D. O'Connor-McCourt, Christiane Cantin, Anne E.G. Lenferink
Life of this patent
Estimating the term…
Abstract
Antibodies which target clusterin, a protein involved in the epithelial-to-mesenchymal transition of carcinoma cells, are identified and characterized. The antibodies may be used to modulate tumour cell activity through binding the clusterin.
Claims21
1-30. (canceled)
A monoclonal antibody or antigen binding fragment capable of specific binding to a β-subunit of human clusterin, wherein said monoclonal antibody binds to an epitope including amino acids 421-443 of the β-subunit of human clusterin more efficiently than a second monoclonal antibody raised against a synthetic peptide including or comprised within said epitope.
A monoclonal antibody or an antigen binding fragment capable of specific binding to a β-subunit of human clusterin, wherein said monoclonal antibody binds to an epitope including amino acids 421-443 of the β-subunit of human clusterin and comprises a) a light chain variable region;
- and b) a heavy chain variable region comprising a CDR1 as set forth in SEQ ID NO.:6 and a CDR2 as set forth in SEQ ID NO.:7.
A conjugate comprising a) an antibody or antigen binding fragment capable of specific binding to a β-subunit of human clusterin, wherein said monoclonal antibody binds to an epitope including amino acids 421-443 of the β-subunit of human clusterin and b) an agent having anti-tumor activity or a contrast agent.
The pharmaceutical composition, wherein the agent having anti-tumor activity is a toxin.
Dependencies are inferred from the claim text.